METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free SurvivalBusiness Wire • 06/03/24
TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in GermanyBusiness Wire • 05/23/24
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from PharmakonBusiness Wire • 05/02/24
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/25/24
Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024Business Wire • 04/24/24
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024Business Wire • 04/05/24
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?Zacks Investment Research • 03/28/24
NovoCure device slows spread of lung cancer to brain in late-stage study; shares riseProactive Investors • 03/27/24
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerBusiness Wire • 03/27/24
Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer TreatmentInvestors Business Daily • 03/27/24